A novel chiral oxazoline copper(<scp>ii</scp>)-based complex inhibits ovarian cancer growth<i>in vitro</i>and<i>in vivo</i>by regulating VEGF/VEGFR2 downstream signaling pathways and apoptosis factors

Abstract

by inhibiting tumor cells from inducing vascular endothelial cells to form their own vasculature and by inhibiting the expression of the anti-apoptotic protein Bcl-2 and up-regulating the expression of the pro-apoptotic proteins Caspase-9 and Bax to induce apoptosis of tumor cells.